
ãå šå1åããšãæ£æ©1æéãã®å¥åº·å¹æãã»ãŒåãã ã£ãïœVILPAç ç©¶ãèŠããéåã®åžžè
1åãš53å
ãã®2ã€ã®æ°åããèªåã®éåã«å¯Ÿããèãæ¹ãå®å šã«å€ããã
æ¯ãäžãã1åãæ£æ©ãã53åã
æ»äº¡ãªã¹ã¯ã®äžããå¹
ããã»ãŒåãã ã£ãã
ããããªãããªãã ãããšæã£ããèªåãæåã¯ããæã£ãã
7äž3,000人ã®ããŒã¿ãèŠããŸã§ã¯ã
14幎éã®ãæé žçŽ ãã¯ãå¿èã«ã¯å±ããŠããªãã£ã
èªåã«ã¯æãåœããç¯ããã£ãã
20幎以äžãã¬ãŒãã³ã°ãç¶ããŠããããã³ããã¬ã¹ã¯140kgãã¹ã¯ã¯ããã¯180kgãçåã«ã¯èªä¿¡ãããã
ãã ããæåã®14幎éã®ãæé žçŽ éåãã¯ãçãã¬åŸã®ãã¬ãããã«30åãåŸæãã€ããŠãå¿ææ°ãèŠãªããããã©ãã©ãšæ©ãããããã§æé žçŽ ããã£ããå®ç§ããšæ¬æ°ã§æã£ãŠããã
3幎åããã«ãŠã§ãŒåŒHIITãåããŠãã£ãæ¥ã®ããšãä»ã§ãèŠããŠããã
ãšã¢ããã€ã¯ã§4åéãå šåãåºãåãã ãã®ã¡ãã¥ãŒããã£ã4åã§ç«ãŠãªããªã£ãã
ãã®æ¥ã«æã£ãã14幎éã®æé žçŽ ã¯ãå¿èºã«ã¯äœãæ®ããŠããªãã£ãã
ãããŠHIITãç¶ããŠ3幎ãå®éæå¿ææ°ã¯äžãããéæ®µã§ã¯æ¯ãåããªããªããååŸã¯å¥äººã®ããã«éäžãç¶ãããã«ãªã£ããäœæãšããŠãå šåã®æéããå¿èãå€ããããšã¯ãèªåã®èº«äœã§ç¥ã£ãŠããã
ãã®è«æã®7äžäººã®ããŒã¿ã¯ããã®äœæãšéãªã£ãŠããã
âŒ æ¬æ Œçã«"4åÃ4ã»ãã"ããããããªã£ã人ãžïŒç¡æïŒ
50代ã®å¿èã30ä»£ã«æ»ãããã«ãŠã§ãŒåŒHIITãå®å
šç
VILPAããã¹ããæéã«1åããªãããã£ã¡ã¯ãé±2å40åãæ¬æ°ã§å¿èãéãããæ¹ã®è©±ã20幎以äžçãã¬ããŠããå»è
ããžã§ã®ã³ã°ã ãã®ã¡ãã¥ãŒãå€ããçç±ããæžããŠããã
WHOã®ã1:2ã«ãŒã«ããããŠã§ã¢ã©ãã«ã§æž¬ãçŽãã
ãŸããäžçäžã®éåã¬ã€ãã©ã€ã³ã®åå°ã«ãªã£ãŠããæ°åãç¥ã£ãŠã»ããã
ãæ¿ããéå1åïŒäžåŒ·åºŠã®éå2åã
WHOãç±³åœã®éåã¬ã€ãã©ã€ã³ã§ã¯ããã®1:2ãåæã«ãå°ãªããšãé±150åã®äžåŒ·åºŠã®éåããŸãã¯75åã®é«åŒ·åºŠã®éåããæšå¥šãããŠããã
1:2ããã®æç®æ¯ã¯äœå幎ã䜿ãããŠããåžžèäžã®åžžèã ã
åé¡ã¯ããã®æ°åãã©ããã£ãŠåºãŠãããã

1:2ã®åå°ã«ã¯ãMETïŒéåã®åŒ·åºŠãæ°å€åãããã®ïŒã«ãããšãã«ã®ãŒæ¶è²»éã®æç®ããããé«åŒ·åºŠã¯äžåŒ·åºŠã®ããã2åãçå±ãšããŠã¯çãéã£ãŠããã
ãã ããæ»äº¡ãå¿è¡ç®¡çŸæ£ã«å¯Ÿããéã¿ãŸã§æ¬åœã«1:2ãªã®ãããããæ¯ããŠããç«åŠããŒã¿ã®å€ãã¯ãå é±ã©ããããéåããŸãããïŒããšèãã¢ã³ã±ãŒãã ã£ãã
人éã®èšæ¶ãã©ããããææ§ãã¯ãå»è ããã£ãŠããã°å«ãšããã»ã©ãããã倿¥ã§ãé£äºã¯ã©ãã§ããïŒããšèããŠè¿ã£ãŠããçããšãå®éã®é£äºå 容ãäžèŽããããšã¯ã»ãšãã©ãªãã
éåãåãã ããžã ã§30åèµ°ã£ãããšã¯èŠããŠããŠããé§ ã®éæ®µãæ¥ãã§äžã£ã20ç§ã¯å¿ããŠããã
ãéåããŠãªãã®ã«å¥åº·ãªäººãã®è¬
å»è ããã£ãŠãããšããšãã©ãäžæè°ãªæ£è ããã«åºäŒãã
ãéåã¯ããŠãŸããïŒãããããç¹ã«äœãã
ãªã®ã«å¿èºæ©èœãé«ããè¡å§ãè¡ç³ãå®å®ããŠãããå¥èšºã®æ°å€ãå幎代ããæããã«ããããããã人ããªãå¥åº·ãªã®ãããã£ãšãäœè³ªãã§çã¥ããŠããã
ãšããã2022幎ããã®è¬ã«çããç ç©¶ãçºè¡šãããã
ã·ãããŒå€§åŠã®Stamatakisææã®ããŒã ãããéåããŠããªãããšèªå·±ç³åãã25,241人ã«ãŠã§ã¢ã©ãã«ãè£ çããŠãå®éã®åããæž¬ã£ãã
ãããšãéåããŠããªããã¯ãã®äººãã¡ã®æ¥åžžããã1ã2åã®æ¿ããèº«äœæŽ»åãæ¬¡ã ãšæ€åºãããã
é§ ã®é段ãå šåã§é§ãäžããããã¹ã«èµ°ã£ãŠä¹ã蟌ããåã©ããšè¿œãããã£ãããããç¬ã®æ£æ©ã§äžç·ã«èµ°ããåéãè·ç©ãæã£ãŠæ©æ©ãããã
âŠã¡ãªã¿ã«ãã®ãªã¹ããèªãã§ãèªåããã£ãŠããããšæã£ã人ãããã¯ãã¶ãVILPAã ã
ç ç©¶ããŒã ã¯ãããVILPAïŒVigorous Intermittent Lifestyle Physical ActivityïŒæ¥åžžç掻ã«åã蟌ãŸããçæéã®é«åŒ·åºŠéåïŒãšåã¥ããã
é©ãã¹ãã¯ããã®ãç¡æèã®å šåãã®ã€ã³ãã¯ãã ã
1æ¥ãã£ã3åçšåºŠã1ã2åã®VILPAãããŠãã人ã¯ããŸã£ããããŠããªãäººãšæ¯ã¹ãŠå šæ»äº¡ãªã¹ã¯ã38ã40%äœããå¿è¡ç®¡æ»äº¡ãªã¹ã¯ã«è³ã£ãŠã¯48ã49%äœãã£ãã

ã€ãŸããéåããŠãªãã®ã«å¥åº·ãªäººãã®äžéšã¯ãæ¥åžžã®äžã§ç¡æèã«ãå šåã®ç¬éããæã£ãŠããã®ãããããªããã¢ã³ã±ãŒãã§ã¯æŸããªãã£ããã®1ã2åãå€ã人ã»ã©ãå¿è¡ç®¡æ»äº¡ãå°ãªãã£ãã
ãã®çºèŠãããããŒã ããæ¬¡ã«åãçµãã ã®ãåé ã®ç ç©¶ã ã
7äž3,485人ã«ãŠã§ã¢ã©ãã«ãã€ããŠæž¬ãçŽãã
2025幎ãåãStamatakisææã®ããŒã ããããã«å€§èŠæš¡ãªæ€èšŒã«èžã¿èŸŒãã ã
VILPAã®çºèŠã§ãçæéã®é«åŒ·åºŠãæ¥åžžã«åãããŠãããããšãããã£ããã§ã¯ãé«åŒ·åºŠã®éå1åã¯ãäžåŒ·åºŠã軜ãéåã®äœåã«çžåœããã®ããåŸæ¥ã®ã1:2ãã¯æ¬åœã«æ£ããã®ãã
ãã ããä»åã®ç ç©¶ã¯VILPAã ããåãåºãããã®ã§ã¯ãªããéåãæ¥åžžåäœããåããããã¹ãŠã®æŽ»åæéãé«åŒ·åºŠãäžåŒ·åºŠãè»œãæŽ»åã«åããŠæ¯ã¹ãŠããã
UK Biobankã«åå ããå¹³å61.6æ³ã®73,485人ãããŠã§ã¢ã©ãã«ããã€ã¹ïŒå é床èšïŒã7æ¥éè£ çããã10ç§ããšã«æŽ»åã®åŒ·åºŠãèšé²ãããã®åŸã®ç æ°ãæ»äº¡ãå¹³å8幎é远跡ããŠããã
èªå·±ç³åã§ã¯ãªããæ©æ¢°ã10ç§å»ã¿ã§å šéšèšé²ããã
远跡ããã¢ãŠãã«ã ã¯6ã€ã
ã»å šæ»äº¡ãªã¹ã¯
ã»å¿è¡ç®¡æ»äº¡ãªã¹ã¯
ã»äž»èŠå¿è¡ç®¡ã€ãã³ãïŒå¿çæ¢å¡ãè³åäžãªã©ïŒ
ã»2åç³å°¿ç ã®çºç
ã»ããé¢é£æ»äº¡
ã»ããé¢é£ã®çºç
7äžäººã10ç§å»ã¿ãå¹³å8幎远跡ã匷床ããšã«ãäœåã«çžåœããããããããã ãå¹ åºãç æ°ã§èª¿ã¹ãç ç©¶ã¯åããŠã ã£ãã
çµæïŒ1:2ã§ã¯ãªãã1:4ã1:9ã ã£ã
çµæã¯è¡æçã ã£ãã
é«åŒ·åºŠã®éå1åéã§åŸããããªã¹ã¯äœäžããäžåŒ·åºŠã®éåã§éæããã®ã«å¿ èŠãªæéã以äžã ã

1:2ã§ã¯ãªãã£ããå¿è¡ç®¡æ»äº¡ã«è³ã£ãŠã¯1:8ã
é«åŒ·åºŠéå1åãšåãäœäžå¹
ã«ãäžåŒ·åºŠéåã§ã¯çŽ8åãããã
ã軜ãéåããšã®æ¯èŒã¯ãã£ãšéãã
æ£æ©ã®ãããªãããéåãšé«åŒ·åºŠéåãæ¯èŒãããšã
é«åŒ·åºŠéå1åïŒæ£æ©53åã94åã
èè ãã«ãããšãã¢ã³ã±ãŒãã«é Œã£ããããŸã§ã®ç ç©¶ã¯ãé«åŒ·åºŠã®éåã®å¹æã2ã4åå°ããèŠç©ãã£ãŠããå¯èœæ§ãããã
ãããããã®1åã¯äžåºŠã«èµ°ãåã£ã1åã§ã¯ãªãã10ç§åäœã§æŸã£ãé«åŒ·åºŠæŽ»åãã1æ¥åè¶³ããæéã ã
ãã ããã®æ°åã¯çŽæ¥å¯Ÿæ±ºã§ã¯ãªãã
å šå1åã®äººã𿣿©53åã®äººãç¡äœçºã«åãã詊éšã§ã¯ãªããååŒ·åºŠã®æŽ»åæéãšæ»äº¡ã»ç æ°ãšã®é¢é£æ²ç·ããæç®ãããã®ã ãæŽ»åãæž¬ã£ãã®ã7æ¥éã ãã芳å¯ç ç©¶ãªã®ã§ãå æ°ã ããé«åŒ·åºŠã§åããããšããéå æã¯æ®ãã
ã ããã1åèµ°ãã°ã53åæ©ããªããŠãããã§ã¯ãªãã
ããã§ããè€æ°ã®ç°ãªãç ç©¶ãäžè²«ããŠã匷床ãé«ãã»ã©å¹çãããããšããçµæã瀺ããŠãããèªåã®3幎éã®äœæãšãäžèŽãããå®ç§ãªå æèšŒæã§ã¯ãªãããæ¹åæ§ãšããŠã¯ããªãä¿¡é Œã§ããããŒã¿ã ãšæã£ãŠããã
2026幎7æè¿œèšãVILPAã®ç ç©¶ã¯è±åœã®å€ã«ãåºãã£ã
2026幎7æã«æç®ãæŽãçŽããããã®èšäºã®å ¬éåŸã«å ±åãããç³å°¿ç ç ç©¶ãšãå ¬éæã«æŸããŠããªãã£ã2æ¬ãåããããšãVILPAã®ç ç©¶ã¯å°ãå ãžé²ãã ã
2026幎4æãäœæéåãããŠããªã22,706人ãå¹³å7.9幎远ã£ãç ç©¶ãå ±åããããVILPAããŒãã ã£ãäººãšæ¯ã¹ãäžå€®å€ã®1æ¥3.9åã ã£ã人ã§ã¯2åç³å°¿ç ã®çºçãã¶ãŒãã36ïŒ äœãã£ãã
ç±³åœã®å šåœèª¿æ»ã«åå ãã3,293人ã§ã¯ã1æ¥5.3åã®VILPAãå šæ»äº¡ãã¶ãŒã44ïŒ äœäžãšé¢é£ããŠããããã ããå¿è¡ç®¡çŸæ£ãããããã£ã人ãé€ããšã95ïŒ ä¿¡é Œåºéã¯1ããŸããã ãå æ°ã ããVILPAãã§ããå¯èœæ§ã¯ããŸã æ®ãã
UK Biobankã®ããŒã¿ã ãã®äžçºãã¿ã§ã¯ãªããªã£ãã芳å¯ç ç©¶ã¯è±åœã®å€ãžåºãã£ãŠããŠãå°ãããä»å ¥è©Šéšãå ±åãããŠãããç æ°ãé²ããšèšŒæãããæ®µéã§ã¯ãªããã©ãVILPAã®ä»åŸã楜ãã¿ã ã
ãªãã匷床ãããããŸã§å¹ãã®ã
é«åŒ·åºŠã¯ãçãæéã§å¿èºãšçèãžå€§ããªè² è·ããããã
7äžäººç ç©¶ã§æž¬ã£ãã®ã¯ã掻åã®åŒ·åºŠãšå°æ¥ã®ç
æ°ã»æ»äº¡ãšã®é¢é£ã§ãVO2maxãããã³ã³ããªã¢ãŸã§æž¬ã£ãããã§ã¯ãªãã以äžã¯ãä»ã®ç ç©¶ã§ããã£ãŠããããšã ã

å¿èºã«åŒ·ãåºæ¿ãå ¥ã
VO2maxïŒæå€§é žçŽ æåéïŒã¯ãå¿èºæ©èœã®ããªãä¿¡é Œã§ããææšã§ãããå šæ»äº¡ãªã¹ã¯ãšã匷ãé¢ä¿ãããã€ãªããŒã«ãŒã®ã²ãšã€ã ã
ããã¯äžåŒ·åºŠã®éåã§ãäžããããã©ãé«åŒ·åºŠéåã®æ¹ãã¿ã€ãããäžãããããã
ããã³ã³ããªã¢ã®è³ªãšéãå€ãã
ããã³ã³ããªã¢ã¯çްèã®äžã®ãšãã«ã®ãŒå·¥å Žã ãå 霢ãšãšãã«åããèœã¡ãããã
ã¡ã€ãšãŒã¯ãªããã¯ã®12é±éã®æ¯èŒè©Šéšã§ã¯ãé«éœ¢è ã®HIIT矀ã§ããã³ã³ããªã¢ã®åŒåžèœåã69ïŒ äžãã£ãã
æ¥åžžã®VILPAã1åããã°åãå€åãèµ·ãããšç€ºãã詊éšã§ã¯ãªããããã§ããé«åŒ·åºŠã倧ããªçççåºæ¿ã«ãªãçç±ã¯ãããã
è¡ç³ãçèã«åã蟌ã¿ããããªã
ä»åã®ç ç©¶ã§æç®æ¯ãæã倧ããã£ãã®ããç³å°¿ç ã ãé«åŒ·åºŠæŽ»å1åããäžåŒ·åºŠæŽ»å9.4åã«å¹æµããã
éåã§ã¯ãçåçž®ãã®ãã®ãGLUT4ïŒã°ã«ã³ãŒã¹ãã©ã³ã¹ããŒã¿ãŒïŒã现èèãžåãããã€ã³ã¹ãªã³ãšã¯å¥ã®çµè·¯ã§ããè¡ç³ãçèãžåã蟌ããã
çµå¶è ã®å€æ¥ãããŠãããšãè¡ç³å€ãå°ãé«ã人ã¯é©ãã»ã©å€ããå¿ãããŠéåããæéããªã人ã«ãããçæéã§å¿ææ°ãäžããéåã¯å®è·µããããã
匷床ã®éããäœã®äžã«ã©ããŸã§åºããããæ¥µç«¯ãªåœ¢ã§æ¯ã¹ãç ç©¶ããããè¥ãå¥åº·ãªç·æ§ã30ç§ã®å
šåã6æ¬ããè¿ããšãçŽåŸã®è¡æ¶²ã§ã¿ã³ãã¯è³ªã714çš®é¡å€ãã£ãã90åã®äžåŒ·åºŠã®æé
žçŽ ã§ã¯7çš®é¡ã ã£ããæ¥åžžã®1åãããã£ãšãã€ãéåã®è©±ã ãã匷床ãäžããæå³ããããããã
714察7ãå
šå30ç§Ã6æ¬ããè¡æ¶²ããããŸã§å€ããïœã¹ããªã³ãã»ã€ã³ã¿ãŒãã«ã»ãã¬ãŒãã³ã°ã®ãããïŒã¡ã³ããŒéå®ïŒ
ããããæ£æ©ã¯æå³ãªãã®ãïŒã
æ£æ©ã¯æé«ã®éåã ã
57ç ç©¶ã»35ã³ããŒããéããã¬ãã¥ãŒïŒDing D, et al. Lancet Public Health. 2025ïŒã§ã¯ã1æ¥7,000æ©ã ã£ã人ã¯2,000æ©ã ã£ã人ããå šæ»äº¡ãªã¹ã¯ãçŽ47ïŒ äœãã£ããæ©ãããšã®äŸ¡å€ã¯æºãããªãã
ä»åã®ç ç©¶ãèšã£ãŠããã®ã¯ããåãæéã䜿ããªãã匷床ãäžããæ¹ãå¹çãããããšããããšã
ãããŠæãåççãªã®ã¯ãäž¡æ¹ããããšã ã
æ©ãéã¯æžãããªãããã®äžã«ãæ¯ãäžãã1åãæ··ããã
å¿ããçµå¶è ã«äŒããŠããã1åæŠç¥ã
3幎åãŸã§ãçµå¶è ã«ãéåããŠãŸããïŒããšèããŠãæ©ããŠãŸãããšè¿ã£ãŠãããããããã§ãããç¶ããŠãã ããããšããèšããªãã£ãã
ä»ã¯éãã
ãæ©ãã®ã¯æé«ã§ããã§ããã®äžã«ãæ¯ãäžãã1åãæ··ããŠãã ãããã
ããã§ãããå šåãã¯ã100ã¡ãŒãã«èµ°ã®ãããªå šåçŸèµ°ã§ã¯ãªããæ¯ã匟ã¿ãäŒè©±ãçãåãããããã§ããã
å ·äœçã«ã¯ãã®3ã€ã ãã ã
é§
ã®é段ãããã€ãããéãäžãã
ãšã¹ã«ã¬ãŒã¿ãŒã«ä¹ã£ãŠãã1åããéæ®µãžå€ãããèªåã¯æ¯æã»ãŒããã·ã¥ããŠãããã©ãã¹ãŒãã§é段ãé§ãäžãã人éã¯ã ãã¶ç®ç«ã€ãé£ã®ãµã©ãªãŒãã³ã«äºåºŠèŠãããããšããããè¿·æã«ã¯ãªããªãããã«ã
éåç¿æ £ããªã人ã¯ããŸãéæ©ãã§äžãã°ããã
æ£æ©ã®éäžã«ã1åã ãæ©æ©ããæ··ããã
äŒè©±ãçãåãããããã®é床ã§1åãããã3åããã°ã3åã®é«åŒ·åºŠãæ¥åžžã«å
¥ãã
ãžã ã«è¡ãã人ã¯ãæé
žçŽ ã®æåŸã«1åã ãããŒã¹ãäžããã
30åæ©ããæ¥ã¯ããã®æåŸã®1åã ãæ¯ãäžãããèªåã«ã¯ããã®1åã®åºæ¿ãã¯ã£ããããããçµãã£ããæ°åãããŠããŒã¹ãæ»ãã
ãžã ã«è¡ããªãæ¥ã§ããå¿ææ°ãäžããå Žé¢ã¯äœããã
æ¥åžžã®äžã«ãæ¯ãäžãã1åããä»èŸŒãããŸãã¯ããããã§ããã
ãã®14幎éããããããèšãåãã
èªåã¯14幎éããã©ãã©æé žçŽ ã§ããã£ãæ°ãã«ãªã£ãŠããåŽã®äººéã ã
ãããŠHIITã«åãæ¿ãã3幎éã§ã身äœãå¥ç©ã«ãªã£ãåŽã®äººéã§ãããã
äž¡æ¹ãç¥ã£ãŠãããããããã¯ã£ããèšããã
èªåã«è¶³ããªãã£ãã®ã¯ãéã§ã¯ãªã匷床ã ã£ãã
æéããå¯åºŠã
ãããã20幎以äžãã¬ãŒãã³ã°ãç¶ããŠããèªåã®ä»ã®çµè«ã ã
â ïž æ³šæäºé ïŒå»åž«ãšããŠïŒ
é«åŒ·åºŠã®éåã¯ãå šå¡ã«å®å šãšããããã§ã¯ãªãã以äžã«è©²åœããæ¹ã¯ãå¿ ã䞻治å»ã«çžè«ããŠããå§ããŠã»ããã
ã»å¿çŸæ£ïŒäžæŽèãçå¿çãåŒèçãªã©ïŒãããæ¹
ã»è¡å§ãååã«ç®¡çã§ããŠããªãæ¹
ã»éåäžã«èžçãããŸããæ®æ®µãšéãåŒ·ãæ¯åããåºãæ¹
ã»èãè °ãè¶³éŠã«åé¡ãããæ¹
ã»ç³å°¿ç æ²»çäžã§äœè¡ç³ã®å¿é ãããæ¹
éåç¿æ £ããªã人ãããããªãå šåããã·ã¥ãããå¿ èŠã¯ãªãããŸãã¯éæ©ãããã§ããã
ãå
šå1åãå¹ççããšããç¥èã¯ããããŸã§å®å
šã«éåã§ãã人ã®ããã®ãã®ã ãç¡çã¯çŠç©ã ãå°ããã€äœåãè²ãŠãŠããã®ã倧åã ã
testosteroneãããšã®å¯Ÿè«ã5ã€ã®æåŒ·æçå¥åº·ç¿æ
£ãã§ãVILPAã詳ãã解説ããŠããŸããè¶
ãªã¹ã¹ã¡ã®ç¿æ
£ã ããå³éžããŠã玹ä»ããã®ã§ããã²ã芧ãã ããã
ãŸãšã
WHOã®ãé«åŒ·åºŠ1åïŒäžåŒ·åºŠ2åãã«ãŒã«ãæ¯ããŠããç«åŠããŒã¿ã®å€ãã¯ãèªå·±ç³åã®ã¢ã³ã±ãŒãã ã£ã
7äž3å人ã®ãŠã§ã¢ã©ãã«ç ç©¶ã§ã¯1:4ã1:9ãå¿è¡ç®¡æ»äº¡ã§1:8ã2åç³å°¿ç ã§1:9.4
ãéåããŠããªããäººã®æ¥åžžã«ãé§ éæ®µãåéã§ã®çæéã®å šåïŒVILPAïŒããããå€ã人ã»ã©æ»äº¡ãªã¹ã¯ãäœãã£ã
æ£æ©ãåŠå®ããªããåãæéã䜿ããªãåŒ·åºŠãæ··ãããšå¹çãè·³ãäžãã
é§ ã®é段ãéãäžãã»æ£æ©äžã®1åæ©æ©ãã»æé žçŽ ã®æåŸã®1åã ãããŒã¹ãäžãããããã ã
ãããŸã§èªãã§ãã ãã£ãŠãããããšãããããŸããã
圹ã«ç«ã£ãããã¹ããããããããšããããå±ã¿ã«ãªããŸãã
èªåã®äœã§ã詊ããå¥åº·ã®è©±ããéåã»ç¡ç ã»è¡ç³ã»é£äºã»ãµããªãŸã§ãããããªããŒãã§æžããŠããŸããããã£ãããã©ããŒããŠããããšå¬ããã§ãã
ãã£ãšæ·±ãç¥ãããæ¹ãžïŒé¢é£èšäºïŒ
âŒãçµå±ã©ã®HIITãããã°ããããã§è¿·ã£ããïŒã¡ã³ããŒéå®ïŒ
å
šå1åãç¿æ
£ã«ã§ããäººãæ¬¡ã«è¿·ãã®ããããã«ãŠã§ãŒåŒãšã¿ãã¿åŒã¯äœãéãã®ãããçµå±ã©ããããã°ããã®ããã§ããã©ããåã"HIIT"ã§ããå¹ããšããã¯å¥ç©ã§ãããã€ãã§éžã¶ãšãé 匵ã£ãŠãç²ããã ãã§çµãããŸããé·ãã¿ã€ããçãã¿ã€ãã10åã§çµããã¿ã€ããã©ãéžã³åããããHIITãç®çå¥ã«ãŸãšããŠããŸãã
⌠ä»äºäžã«ã©ãåãã°ãããïŒã¡ã³ããŒéå®ïŒ
1æ¥7æé座ã人ããä»äºäžã«ã§ããå¥åº·ç¿æ
£ãå
šéšãŸãšãã
é§
ã®é段ã ãã§ãªããäŒè°ãæŒé£åŸãååŸã®ç æ°ã座ãã£ã±ãªãã®æéã«ã©ãåãããŸã§èœãšããå®è·µç·šã§ãã30åããšã®åº§äœäžæãé£åŸããã®æ£æ©ãååŸã®é段1åŸåŸ©ãªã©ããå
šå1åããä»äºæ¥ã«æ··ããã人ã«åããŠããŸãã
⌠çãã¬ãæé
žçŽ ãå
šéšã¯ã§ããªã人ãžïŒã¡ã³ããŒéå®ïŒ
çãã¬ãæé
žçŽ ãæé«ã ãã§ãå
šéšã¯ã§ããªã人ãžïœæéããªã人ã®éåé
å
VILPAãHIITãçãã¬ãæ©è¡ãå
šéšå€§äºã ãšããã£ãŠããå¿ãã人ã¯å
šéšã§ããŸãããæéããªã人ãäœãåªå
ããããŸã§æ±ºãããæ¹ã«åããŠããŸãã
ã¡ã³ããŒã·ãããéå¶ããŠããŸãã
ã¡ã³ããŒã·ãããDr.ãããã©ããã§ã¯ãç¡ænoteã§ã¯å
¥å£ãåºãæžããŠããŸããã¡ã³ããŒéå®ã§ã¯ãããããå
ã®å€æé åºãšãå®ç掻ã§ã®çµã¿æ¹ãŸã§æžããŠããŸãã
æ€æ»å€ãç¡ç ãè¡ç³ãéåãäŒé£ãã©ã䞊ã¹ãŠå€æããããŸã§æŽçãããæ¹ã¯ãDr.ãããã©ãã§èªããŸãã
æé¡1000åã§åå ã§ããŸããåããªãã£ãããããè§£çŽã§ããŸãã
åèæç®
1) Biswas RK, Ahmadi MN, Bauman A, Milton K, Koemel NA, Stamatakis E. Wearable device-based health equivalence of different physical activity intensities against mortality, cardiometabolic disease, and cancer. Nature Communications. 2025;16:8315. doi:10.1038/s41467-025-63475-2
2) Stamatakis E, Ahmadi MN, Gill JMR, et al. Association of wearable device-measured vigorous intermittent lifestyle physical activity with mortality. Nature Medicine. 2022;28:2521-2529. doi:10.1038/s41591-022-02100-x
3) Ding D, et al. Daily steps and health outcomes in adults: a systematic review and dose-response meta-analysis. Lancet Public Health. 2025;10(8):e668-e681. doi:10.1016/S2468-2667(25)00164-1
4) Robinson MM, Dasari S, Konopka AR, et al. Enhanced Protein Translation Underlies Improved Metabolic and Physical Adaptations to Different Exercise Training Modes in Young and Old Humans. Cell Metabolism. 2017;25(3):581-592. doi:10.1016/j.cmet.2017.02.009
5) Chong KH, Ahmadi MN, Biswas RK, et al. Dose-Response Associations of Intermittent Lifestyle Physical Activity Micropatterns and Incident Type 2 Diabetes. Diabetes Care. 2026;49(6):1086-1094. doi:10.2337/dc25-3018
6) Koemel NA, Ahmadi MN, Biswas RK, et al. Vigorous intermittent lifestyle physical activity (VILPA) and mortality risk among US adults: a wearables-based national cohort study. International Journal of Behavioral Nutrition and Physical Activity. 2026;23(1):17. doi:10.1186/s12966-026-01876-2
7) Pang B, Moullin JC, Thompson C, et al. Testing a vigorous intermittent lifestyle physical activity intervention in adults transitioning to retirement: a pilot randomised controlled trial. Age and Ageing. 2025;54(9):afaf244. doi:10.1093/ageing/afaf244
8) Kodama S, Saito K, Tanaka S, et al. Cardiorespiratory fitness as a quantitative predictor of all-cause mortality and cardiovascular events in healthy men and women: a meta-analysis. JAMA. 2009;301(19):2024-2035. doi:10.1001/jama.2009.681
9) Mandsager K, Harb S, Cremer P, et al. Association of Cardiorespiratory Fitness With Long-term Mortality Among Adults Undergoing Exercise Treadmill Testing. JAMA Netw Open. 2018;1(6):e183605. doi:10.1001/jamanetworkopen.2018.3605
10) MilanoviÄ Z, SporiÅ¡ G, Weston M. Effectiveness of High-Intensity Interval Training (HIT) and Continuous Endurance Training for VO2max Improvements: A Systematic Review and Meta-Analysis of Controlled Trials. Sports Med. 2015;45(10):1469-1481. doi:10.1007/s40279-015-0365-0
11) Richter EA, Hargreaves M. Exercise, GLUT4, and skeletal muscle glucose uptake. Physiol Rev. 2013;93(3):993-1017. doi:10.1152/physrev.00038.2012
12) Sylow L, Kleinert M, Richter EA, Jensen TE. Exercise-stimulated glucose uptake - regulation and implications for glycaemic control. Nat Rev Endocrinol. 2017;13(3):133-148. doi:10.1038/nrendo.2016.162
â»æ¬èšäºã¯äžè¬çãªå¥åº·ã»å»åŠæ å ±ã®æäŸãç®çãšãããã®ã§ãããç¹å®ã®å人ã«å¯Ÿãã蚺æã»æ²»çã»å»åŠçå©èšãè¡ããã®ã§ã¯ãããŸãããå¥åº·äžã®æžå¿µãããå Žåã¯ãå¿ ãå»çæ©é¢ãå蚺ããŠãã ãããèšäºã®æ å ±ã«åºã¥ãè¡åã®çµæã«ã€ããŠã¯ãçè ã¯è²¬ä»»ãè² ããããŸãã